HomeNewsBusinessInfosys inks long-term pact with the German firm LANXESS for digital and workplace transformation

Infosys inks long-term pact with the German firm LANXESS for digital and workplace transformation

Early last week, Infosys won a large deal with the investment management firm Vanguard for digital transformation.

July 20, 2020 / 19:41 IST
Story continues below Advertisement

Indian IT firm Infosys and German firm LANXESS entered into a long term partnership for digital and workplace transformation. LANXESS manufactures chemical intermediates, additives, specialty chemicals in Germany.

As a part of the tie-up, India’s second-largest IT services firm will support LANXESS in its IT infrastructure digitisation strategy and enable its global workforce spread across 33 countries using a secure and fully managed modern workplace, according to a company statement.

Story continues below Advertisement

Infosys will set up end-user centric modern workplace, which supports multi-lingual artificial intelligence-powered service desk operating from Europe and India for the LANXESS’s workforce, the statement added.

Germany is a very strategic market for Infosys and is an important part of the localisation strategy in Europe, said Jasmeet Singh, Executive Vice President and Global Head of Manufacturing at Infosys.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show